Scott Dryden-Peterson

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Increased risk of severe infant anemia after exposure to maternal HAART, Botswana
    Scott Dryden-Peterson
    Department of Medicine, Division of Infectious Diseases, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Acquir Immune Defic Syndr 56:428-36. 2011
  2. pmc Highly active antiretroviral therapy versus zidovudine for prevention of mother-to-child transmission in a programmatic setting, Botswana
    Scott Dryden-Peterson
    Department of Medicine, Division of Infectious Diseases, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Acquir Immune Defic Syndr 58:353-7. 2011
  3. pmc Cotrimoxazole prophylaxis and risk of severe anemia or severe neutropenia in HAART-exposed, HIV-uninfected infants
    Scott Dryden-Peterson
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts, United States of America Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, United States of America
    PLoS ONE 8:e74171. 2013
  4. pmc Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in Botswana
    Kathleen M Powis
    Department of Internal Medicine and Pediatrics, Massachusetts General Hospital, Boston, MA, USA
    J Acquir Immune Defic Syndr 56:131-8. 2011
  5. pmc Risk factors for mortality among human immunodeficiency virus-exposed and unexposed infants admitted to a neonatal intensive care unit in Botswana
    Rebecca M Zash
    Division of Infectious Disease, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States Botswana Harvard AIDS Institute Partnership for HIV Research and Education, Gaborone, Botswana
    J Paediatr Child Health 50:189-95. 2014
  6. pmc Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana
    Jennifer Y Chen
    Department of Medicine, Brigham and Women s Hospital, Berlin, Germany
    J Infect Dis 206:1695-705. 2012
  7. pmc High mortality associated with retreatment of tuberculosis in a clinic in Kampala, Uganda: a retrospective study
    Carlos Acuna-Villaorduna
    Section of Infectious Diseases, Department of Medicine, Boston Medical Center and Boston University School of Medicine, Boston, Massachusetts Makerere University Boston Medical Center Research Collaboration, Kampala, Uganda Division of Infectious Diseases, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts Medical Research Council Uganda Virus Research Institute, Uganda Research Unit on AIDS, Entebbe, Uganda Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda Section of Infectious Diseases, Department of Medicine, New Jersey Medical School Rutgers University, Newark, New Jersey Division of Infectious Diseases and Global Medicine, Department of Medicine, University of Florida, Gainesville, Florida Mulago Hospital Tuberculosis Clinic, Mulago Hospital, Kampala, Uganda
    Am J Trop Med Hyg 93:73-5. 2015
  8. pmc Initial programmatic implementation of WHO option B in Botswana associated with increased projected MTCT
    Scott Dryden-Peterson
    Department of Medicine, Division of Infectious Diseases, Brigham and Women s Hospital, Boston, MA Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA Department of Medicine, Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, MA Department of Biostatistics, Harvard School of Public Health, Boston, MA Department of Medicine, Division of Gastroenterology, Massachusetts General Hospital, Boston, MA Department of Pathology, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana and Department of HIV AIDS Prevention and Care, Ministry of Health, Gaborone, Botswana
    J Acquir Immune Defic Syndr 68:245-9. 2015
  9. pmc An augmented SMS intervention to improve access to antenatal CD4 testing and ART initiation in HIV-infected pregnant women: a cluster randomized trial
    Scott Dryden-Peterson
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts, United States of America Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, United States of America Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 10:e0117181. 2015
  10. doi request reprint Antiretroviral treatment initiation among HIV-infected pregnant women with low CD4(+) cell counts in Gaborone, Botswana
    Jennifer Y Chen
    Harvard Medical School, Boston, MA, USA
    J Acquir Immune Defic Syndr 54:102-6. 2010

Collaborators

Detail Information

Publications11

  1. pmc Increased risk of severe infant anemia after exposure to maternal HAART, Botswana
    Scott Dryden-Peterson
    Department of Medicine, Division of Infectious Diseases, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Acquir Immune Defic Syndr 56:428-36. 2011
    ..Maternal highly-active antiretroviral therapy (HAART) reduces mother-to-child HIV transmission but may increase the risk for infant anemia...
  2. pmc Highly active antiretroviral therapy versus zidovudine for prevention of mother-to-child transmission in a programmatic setting, Botswana
    Scott Dryden-Peterson
    Department of Medicine, Division of Infectious Diseases, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Acquir Immune Defic Syndr 58:353-7. 2011
    ..Maternal HAART was associated with decreased prevention of mother-to-child transmission (P = 0.001) and improved HIV-free survival (P = 0.040) compared with zidovudine (with or without single-dose nevirapine) in a programmatic setting...
  3. pmc Cotrimoxazole prophylaxis and risk of severe anemia or severe neutropenia in HAART-exposed, HIV-uninfected infants
    Scott Dryden-Peterson
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts, United States of America Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, United States of America
    PLoS ONE 8:e74171. 2013
    ..Prophylactic cotrimoxazole is recommended for infants born to HIV-infected mothers. However, cotrimoxazole may increase the risk of severe anemia or neutropenia...
  4. pmc Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in Botswana
    Kathleen M Powis
    Department of Internal Medicine and Pediatrics, Massachusetts General Hospital, Boston, MA, USA
    J Acquir Immune Defic Syndr 56:131-8. 2011
    ..The impact of in utero exposure to highly active antiretroviral therapy (HAART) on longitudinal growth of HIV-uninfected infants is unknown...
  5. pmc Risk factors for mortality among human immunodeficiency virus-exposed and unexposed infants admitted to a neonatal intensive care unit in Botswana
    Rebecca M Zash
    Division of Infectious Disease, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States Botswana Harvard AIDS Institute Partnership for HIV Research and Education, Gaborone, Botswana
    J Paediatr Child Health 50:189-95. 2014
    ..We describe risk factors for NNU mortality in an area with high prevalence of human immunodeficiency virus (HIV)...
  6. pmc Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana
    Jennifer Y Chen
    Department of Medicine, Brigham and Women s Hospital, Berlin, Germany
    J Infect Dis 206:1695-705. 2012
    ..It is unknown whether adverse birth outcomes are associated with maternal highly active antiretroviral therapy (HAART) in pregnancy, particularly in resource-limited settings...
  7. pmc High mortality associated with retreatment of tuberculosis in a clinic in Kampala, Uganda: a retrospective study
    Carlos Acuna-Villaorduna
    Section of Infectious Diseases, Department of Medicine, Boston Medical Center and Boston University School of Medicine, Boston, Massachusetts Makerere University Boston Medical Center Research Collaboration, Kampala, Uganda Division of Infectious Diseases, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts Medical Research Council Uganda Virus Research Institute, Uganda Research Unit on AIDS, Entebbe, Uganda Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda Section of Infectious Diseases, Department of Medicine, New Jersey Medical School Rutgers University, Newark, New Jersey Division of Infectious Diseases and Global Medicine, Department of Medicine, University of Florida, Gainesville, Florida Mulago Hospital Tuberculosis Clinic, Mulago Hospital, Kampala, Uganda
    Am J Trop Med Hyg 93:73-5. 2015
    ..Patients were traced to determine their vital status; 62% (234/377) patients were found dead. Having ≤ 2 treatment courses and not completing retreatment were associated with mortality in adjusted analyses. ..
  8. pmc Initial programmatic implementation of WHO option B in Botswana associated with increased projected MTCT
    Scott Dryden-Peterson
    Department of Medicine, Division of Infectious Diseases, Brigham and Women s Hospital, Boston, MA Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA Department of Medicine, Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, MA Department of Biostatistics, Harvard School of Public Health, Boston, MA Department of Medicine, Division of Gastroenterology, Massachusetts General Hospital, Boston, MA Department of Pathology, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana and Department of HIV AIDS Prevention and Care, Ministry of Health, Gaborone, Botswana
    J Acquir Immune Defic Syndr 68:245-9. 2015
    ..79% under Option A and 4.69% under Option B (P < 0.001). Successful implementation of Option B or B+ may require that ART can be initiated within antenatal clinics, and novel strategies to remove barriers to rapid ART initiation. ..
  9. pmc An augmented SMS intervention to improve access to antenatal CD4 testing and ART initiation in HIV-infected pregnant women: a cluster randomized trial
    Scott Dryden-Peterson
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts, United States of America Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, United States of America Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 10:e0117181. 2015
    ..We evaluated the effectiveness of an SMS-based intervention to improve access to timely antenatal ART...
  10. doi request reprint Antiretroviral treatment initiation among HIV-infected pregnant women with low CD4(+) cell counts in Gaborone, Botswana
    Jennifer Y Chen
    Harvard Medical School, Boston, MA, USA
    J Acquir Immune Defic Syndr 54:102-6. 2010
    ..We analyzed rates of HIV testing, CD4 cell count testing, and HAART initiation during pregnancy...
  11. pmc Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study
    Edward C Jones-Lopez
    Section of Infectious Diseases, Department of Medicine, Boston Medical Center, Boston University Medical School, Boston, Massachusetts, USA
    PLoS Med 8:e1000427. 2011
    ..The effectiveness of this retreatment regimen has not been systematically evaluated...